Kihealth Europe
Precision medicine and metabolic disease innovation pipeline

One platform. One disease area. Complete laboratory and clinical validation.

Kihealth Europe is exclusively focused on metabolic disease. Intercept IQ™ and the BetaIntercept™ T1D and T2D programmes have completed full laboratory and clinical validation, translating multi-omic liquid-biopsy science into actionable diagnostic insight.

Foundational Platform

Intercept IQ™

Liquid-biopsy intelligence for metabolic disease

Tissue-resolved cfDNA · methylation · fragmentomics

Phase · Clinical Studies100%
Programme context

Intercept IQ™ has completed full laboratory and clinical validation as a multi-omic platform. It integrates ultra-deep cell-free DNA sequencing, beta-cell-specific methylation signatures, fragmentomics and machine-learned tissue-of-origin inference, all powered by KI Intelligence, our proprietary AI engine.

Milestone history
  1. 2023Beta-cell methylation atlas locked
  2. 2024Analytical validation completed across reference cohorts
  3. 2026Clinical-grade pipeline release and external benchmarking completed
Next milestone

Expansive clinical validation in European cohorts

Type 1 Diabetes

BetaIntercept™ T1D

Beta-cell injury and loss in Type 1 Diabetes

Beta-cell unmethylated INS cfDNA

Phase · Clinical Studies100%
Programme context

BetaIntercept™ T1D has completed full laboratory and clinical validation. It is designed to evaluate active beta-cell destruction across Stage 1–3 T1D, supporting earlier intervention strategies and the emerging European disease-modifying therapy landscape.

Milestone history
  1. 2023Analytical validation completed
  2. 2024Prospective paediatric cohort (n≈1,840) read out completed
  3. 2026European pivotal-style study pending
Next milestone

Expansive clinical validation in European cohorts

Type 2 Diabetes

BetaIntercept™ T2D

Beta-cell stress, dysfunction and progression in Type 2 Diabetes

Multi-tissue metabolic methylation panel

Phase · Clinical Studies100%
Programme context

BetaIntercept™ T2D has completed full laboratory and clinical validation. The multi-tissue panel surfaces beta-cell stress and dysfunction long before HbA1c moves — supporting research into staging, progression and therapeutic response in Type 2 Diabetes.

Milestone history
  1. 2024Discovery cohort locked
  2. 2025Analytical validation completed
  3. 2026Multi-site European clinical validation pending
Next milestone

Expansive clinical validation in European cohorts

BetaIntercept™ collection kits

Physician-ordered, CLIA-certified molecular diagnostic kits. A simple venous blood draw captures cfDNA, autoantibody and metabolic signals — shipped back to Kihealth Labs for multi-omic analysis.

Type 1 Diabetes

BetaIntercept™ T1D

Molecular diagnostic kit integrating Beta Cell Score™, insulin, C-peptide and HbA1c — from a single venous blood draw.

  • · 2 blood collection tubes
  • · Biohazard specimen bag
  • · Prepaid return shipping
  • · Cold pack & prep pad
  • · Provider collection guide
  • · CLIA-certified analysis
Type 2 Diabetes

BetaIntercept™ T2D

Molecular diagnostic kit integrating Beta Cell Score™, insulin, C-peptide and HbA1c — from a single venous blood draw.

  • · 2 blood collection tubes
  • · Biohazard specimen bag
  • · Prepaid return shipping
  • · Cold pack & prep pad
  • · Provider collection guide
  • · CLIA-certified analysis

Considering co-development, biobank access, or a European clinical site?

Partnership Opportunities Validation Evidence